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Background: The symptom anosognosia or unawareness of disease in dementia has
mainly been studied in patients with late-onset dementia (LOD, ≥65 years), whereas little
is known on whether it is also present in patients with early-onset dementia (EOD, <65
years). We aimed at investigating differences in anosognosia between LOD and EOD, by
also studying its association with different clinical variants of EOD and the presence of
neuropsychiatric symptoms.
Methods: A total of 148 patients, 91 EOD and 57 LOD, were recruited and
underwent extended clinical assessment and caregiver interview that included
questionnaires aimed at measuring anosognosia and neuropsychiatric symptoms.
Differences in anosognosia between EOD and LOD and between subgroups with
different clinical variants were investigated, as well as correlation between anosognosia
and neuropsychiatric symptoms. A regression analysis was applied to explore the
association between anosognosia and development of neuropsychiatric symptoms
during disease progression.
Results: Median levels of anosognosia were not significantly different between EOD
and LOD. Anosognosia increased overtime with disease progression and was higher
in frontotemporal dementia patients or, more precisely, in frontotemporal dementia and
Alzheimer’s disease variants associated with involvement of the frontal lobes. Higher
levels of early anosognosia were associated with higher frequency and severity of
subsequent neuropsychiatric symptoms, in particular apathy, later in the course of
the disease.
Conclusion: Anosognosia is a frequent symptom of EOD, occurring in 94.5% of
all-cause EOD, and it is associated with higher risk of developing neuropsychiatric
symptoms during disease progression. Recognising anosognosia may be helpful for
clinicians and families to reduce diagnostic delay and improve disease managment.
Keywords: anosognosia, early onset dementia, late onset dementia, neuropsychiatric symptoms, apathy,
Alzheimer’s disease, frontotemporal dementia
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INTRODUCTION
Patients with dementia frequently are not aware of their cognitive
difficulties, a neurological symptom indicated as anosognosia.
Studies have reported that about 10% of patients with mild
dementia have anosognosia and that this proportion increases
up to 80% in patients with severe dementia (1–4), suggesting an
association of anosognosia with dementia severity, as also shown
by longitudinal studies showing that anosognosia increases with
the progression of dementia (5, 6). In addition, anosognosia
is often associated with the presence of neuropsychiatric
symptoms (7, 8).
Research into anosognosia has mainly focused in dementia
in old age [late-onset dementia, ≥65 years, (LOD)]. However,
anosognosia in early-onset dementia (EOD, <65 years) may
potentially have even more detrimental effects on patients and
their families, as these people are more likely to still have
working, parental, and social duties and lack of awareness of
diseasemay expose them to diagnostic delay, reduced compliance
with treatments, and even risky behaviors. Only few studies
have investigated anosognosia in EOD in comparison with
LOD, but their results are conflicting. One first study focusing
on early- vs. late-onset Alzheimer’s disease (AD) found that
AD-EOD were more aware of their cognitive disturbances
(i.e., had less anosognosia) compared to AD-LOD (9); on the
contrary, Dourado et al. did not find significant differences
between these two groups (10). The only study that included
patients with clinical diagnosis other than AD [more precisely
vascular dementia (VaD)] found that EOD patients were more
aware of their cognitive disturbances but had greater functional
impairment than LOD patients (11).
The aim of the present study was to investigate the
presence and degree of anosognosia in groups of patients with
EOD and LOD, including different clinical presentations, by
also studying its association with neuropsychiatric symptoms
and dementia progression overtime. We hypothesized that
anosognosia increases along disease progression and that it might
be associated with development of neuropsychiatric symptoms
during the course of disease.
We anticipated that improving the quantification and
characterization of anosognosia in EOD would help clinicians,
patients, and their family to reduce diagnostic delay and
improve identification of people at greater risk of potentially
dangerous behaviors.
MATERIALS AND METHODS
Patients for this study were recruited from a larger database
established for an epidemiologic study in the province of
Modena, Northern Italy, including prospectively collected cases
from 2017 to 2019 (12). Inclusion criteria were as follows: a
dementia diagnosis with symptoms onset before age 65 (EOD)
or at/after age 65 (LOD), dementia as the principal cause of
disability, having a caregiver available for interview, and being
a resident in the province of Modena. We compared EOD
patients available in our dataset with a cohort of LOD patients
seen in the same clinic without any speculation about their
epidemiology or diagnosis frequencies. For the present study
only, additional inclusion criteria were also the availability
of anosognosia measured when patients had been first seen
in the Modena dementia service (early anosognosia) and at
the moment of recruitment (current anosognosia). Exclusion
criteria included coexisting diagnoses of pervasive developmental
disorder or major psychiatric disorder, and cognitive impairment
in the context of another neurological disorder in which
disability was primarily related to non-cognitive symptoms (e.g.,
multiple sclerosis, cerebrovascular disease with severe motor
disability). For each patient, we collected demographic data,
clinical information such as type of dementia diagnosis at the
moment of recruitment and duration of disease from symptoms
onset until recruitment, neuropsychological measures including
the MMSE (13) at the moment of recruitment (current MMSE)
and when patients had been first seen in the Modena dementia
service (early MMSE), and measurement of anosognosia at
the moment of recruitment (current anosognosia) and when
patients had been first seen in the Modena dementia service
(early anosognosia). Anosognosia was assessed with Clinical
Insight Rating Scale (CIRS) (14). CIRS evaluation is based on
the examiner’s judgement about patient’s level of insight based
on history, neuropsychological testing, or a combination of
them. It defines four domains of patient’s awareness: (a) the
reason for the visit; (b) the cognitive deficits; (c) functional
deficits; and (d) perception of the progression of deficits; based
on a separate interview with the patient and the caregiver,
the items are rated by the examiner as 0 (full insight),
or 1 (partial insight), or 2 (not insight), and summed to
obtain a total score between 0 and 8. In addition, at the
moment of recruitment, additional questionnaires including
the Neuropsychiatry Inventory (NPI) (15) were administered
to obtain a measurement of behavioral and psychological
symptom (current NPI). Twelve neuropsychiatric symptoms
were assessed (delusion, hallucination, agitation, dysphoria,
anxiety, euphoria, apathy, disinhibition, irritability, aberrant
motor behavior, night-time behavioral disturbances, and changes
in appetite/eating behaviors).
The study was approved by local Ethical Committee; it was
conducted according to the Declaration of Helsinki, and patients
signed informed consent (Study Number 186/2016 of the local
ethical committee).
Patients were classified according to the clinical diagnosis
at the moment of recruitment in AD (16) [including amnestic
variant, logopenic variant (17), posterior cortical atrophy
(18) and behavioral/disexecutive variant (19)], VaD (20, 21),
possible or probable dementia with Lewy body (LBD) (22),
frontotemporal dementia (including behavioral variant,
semantic variant of primary progressive aphasia, and non-fluent
agrammatic variant of primary progressive aphasia) (17, 23),
atypical parkinsonism [i.e., progressive sopranuclear palsy (PSP)
or corticobasal degeneration (CBD)] (24).
Descriptive statistics were applied to investigate early and
current degree of anosognosia in EOD and LOD patients, as well
clinical and global cognitive measures. Differences between the
two groups were investigated with parametric or non-parametric
tests as appropriate; t-tests for independent variables or the
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FIGURE 1 | Clinical diagnosis distribution. On the left, clinical diagnosis subgroups in the whole cohort represented by frequency and number of each diagnosis; on
the right, clinical diagnosis distribution for EOD and LOD separately.


























Sex, female (n) 86 56 36 0.285
Education (years), median
(range)
8 (2–18) 8 (3–18) 8 (2–18) 0.121




















3 3 4 0.503
Current anosognosia
(CIRS), median
6 6 6 0.947










Current NPI total, median
(range)
14 (0–57) 15 (0–54) 14 (0–57) 0.802
CIRS, Clinical Insight Rating Scale; NPI, Neuropsychiatry Inventory; MMSE, Mini Mental
State Examination; sd, standard deviation; ns, not significant.
Mann–Whitney test was applied for continuous variables, and
chi-squared test was applied for binary variables. Wilcoxon
signed-rank test was used to investigate differences in cognitive
measures and anosognosia measures between the first visit
and time of recruitment. Multivariable analysis for repeated
measures was applied to examine anosognosia differences in
EOD and LOD at first visit and recruitment. Univariable analysis
was applied to investigate anosognosia differences in diagnostic
subgroups of EOD and LOD; Bonferroni post hoc correction
was applied for diagnostic group variable. The Spearman partial
correlation was used to investigate the associations between
early and current anosognosia and NPI in both groups. For
NPI correlation, given to multiple correlation investigated (12
items), we considered significant a threshold of p < 0.004. Linear
regression model was applied to investigate association between
early anosognosia and presence of neuropsychiatric symptoms at
recruitment assessed with NPI both in the whole cohort and in
EOD and LOD separately. All statistical analyses were performed
with SPSS software for Windows.
RESULTS
Demographical and Clinical Features
A total of 148 consecutive eligible patients were included in the
present study: 91 EOD and 57 LOD. Figure 1 shows distribution
of clinical diagnosis in all group and separately in EOD and
LOD. Table 1 shows clinical and demographical features of the
recruited patients. Considering the whole cohort, 86 patients
were diagnosed as AD (52 EOD, 35 LOD), 28 patients as
FTD (23 EOD, 5 LOD), 12 patients with DLB (3 EOD, 9
LOD), 9 as VaD (6 EOD, 3 LOD), 7 patients with ayptical
parkinsonism (5 EOD, 2 LOD), and 6 with other dementia
(i.e., alcoholic dementia, cerebral amyloid angiopathy; 3 EOD,
3 LOD).
Mean age at recruitment was 70.27 (±8.28) years across the
whole group, 64.90 (±4.82) years in the EOD group, and 78.56
(±5.02) years in the LOD (p < 0.001). Mean disease duration
(defined as the time between symptoms onset and recruitment)
was 5.6 (±3.33) years in the whole group, with no significant
differences (p = 0.32) between EOD (mean disease duration
5.52 ± 3.25 years) and LOD (mean disease duration 6.25 ±
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FIGURE 2 | Boxplot of anosognosia level in EOD and LOD for each diagnostic subgroup; on the left, early anosognosia; on the right, current anosognosia.
2.74 years). There was no difference in sex between EOD and
LOD (p = 0.28). Similarly, there were no significant differences
between EOD and LOD in the MMSE score at the first visit
(mean MMSE 21.48 ± 5.03 for EOD, 22.60 ± 3.57 for LOD, p
= 0.14) or at the moment of recruitment (mean MMSE 15.91
± 8.84 for EOD, 17.50 ± 7.67 for LOD, p = 0.37). At the time
of recruitment, MMSE scores were significantly lower relative to
the first assessment in both EOD and LOD groups (p < 0.001).
There were no differences in the relative proportion of AD (p
= 0.60), VaD (p = 0.74), and atypical parkinsonism (p = 0.70)
between EOD and LOD; on the contrary, FTD diagnosis was
more frequent in the EOD group in comparison to LOD (p =
0.017), while DLB was more frequent in LOD (p = 0.01). Mean
time between first visit and recruitment was 42 months, with
LOD showing longer time compared to EOD (p= 0.003).
Measures of early anosognosia showed that at the first
assessment, 83.5% of patients with EOD and 78.9% patients with
LOD had some degree of anosognosia [i.e., a CIRS score > 1, as
in (25, 26), p = 0.484]. Measures of current anosognosia showed
that these proportions reached 94.5% of EOD and 98.2% of LOD
at the moment of recruitment (p = 0.262). Measuring early and
current anosognosia as a continuous variable still showed that
there were no significant differences between EOD and LOD
at either first assessment (mean early CIRS EOD = 3.90, mean
early CIRS LOD = 3.61, p = 0.50) or time of recruitment (mean
current CIRS EOD = 5.64, mean current CIRS LOD = 5.61, p =
0.94). Current anosognosia values were significantly higher than
values of early anosognosia (p < 0.001), even when controlling
for the effect of MMSE.
Association Between Anosognosia and
Clinical Diagnosis
Comparisons of early anosognosia across different diagnostic
subgroups showed that it varied among different clinical
subgroups independently of age of onset: FTD patients showed
higher mean anosognosia values in comparison to AD patients,
in both EOD (mean CIRS FTD-EOD = 5.39, mean AD-EOD
= 3.16, p < 0.001) and LOD (mean CIRS FTD-LOD = 5.60;
AD-LOD = 3.26, p < 0.001). The same pattern emerged for
current anosognosia, but the differences between FTD and AD
patients did not reach significance. Figure 2 graphically depicts
early and current anosognosia levels by diagnostic subgroup.
We further subdivided each diagnostic group according to
the variant they had presented with, in order to investigate
possible differences in level of anosognosia between presentation
with predominantly cognitive or behavioral symptoms (12).
More precisely, we divided the AD group into amnestic
variant, frontal/dysexecutive variant, logopenic variant of
primary progressive aphasia, and posterior cortical atrophy.
We divided the FTD group into behavioral variant, non-fluent
variant of primary progressive aphasia, and semantic variant of
primary progressive aphasia. We found that patients with the
dysexecutive/frontal variant of AD and those with the behavioral
variant of FTD showed highest levels of both early and current
anosognosia irrespective of age of dementia onset (Figure 3).
More precisely, patients with the behavioral variant of FTD had
higher values of anosognosia than those with the amnestic variant
of AD (p = 0.001), logopenic primary progressive aphasia (p <
0.001), posterior cortical atrophy (p < 0.001), and non-fluent
agrammatic variant of FTD (p = 0.013), whereas there were
no significant differences between patients with the behavioral
variant of FTD compared to those with the frontal/dysexecutive
variant of AD.
Association Between Anosognosia and
Neuropsychiatric Symptoms
When studying the presence of behavioral disturbancesmeasured
by the NPI, either with its total score or individual subscores for
different behavioral symptoms, we found that there was a positive
correlation between early anosognosia and current NPI apathy
subscore (r= 0.267, p= 0.001) across all patients and in the EOD
group only (r = 0.440, p < 0.001), but not in the LOD group
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FIGURE 3 | Boxplot of anosognosia level in EOD and LOD for patients classified based on cognitive/behavioral patterns; on the left, early anosognosia; on the right,
current anosognosia.
only (p = 0.245). There were no significant correlations between
current anosognosia and current NPI total score or subscores, in
either EOD and LOD, as well as across all patients.
A linear regression performed in all patients with current total
NPI score as the dependent variable and early anosognosia and
MMSE as independent variables showed that higher current NPI
scores were associated with higher level of early anosognosia
(standardized coefficient beta = 0.175, p = 0.039, CI 0.047–
0.728). When performing the same analysis in EOD and LOD
separately, such association remained significant in the EOD
group only. When exploring single current NPI subscores in the
whole cohort with regression analysis, a significant association
between current NPI apathy subscore and early anosognosia
was found (standardized coefficient beta = 0.441, p = 0.001, CI
0.194–0.688). Such association was specific for the EOD group
(standardized coefficient beta = 0.745, p < 0.001, CI 0.420–
1.071). The same regression analysis performed by adding disease
duration, time between first visit and recruitment, and diagnostic
subgroup as independent covariates confirmed that current NPI
apathy subscore in the EOD group only was associated with early
anosognosia (standardized coefficient beta= 0.830, p< 0.001, CI
0.353–1.106) and diagnostic subgroup (in particular FTD, VaD,
and atypical parkinsonism; standardized coefficient beta= 0.669,
p= 0.001, CI 0.267–1.071).
DISCUSSION
In this study, we investigated whether there were differences in
the level of anosognosia between individuals with EOD and LOD.
We also tested if anosognosia in EOD differs across different
types of dementia and their clinical variants, and whether it is
associated with neuropsychiatric symptoms.
First, we found that median level of anosognosia was not
significantly different between EOD and LOD. Both EOD
and LOD reported the same degree of early and current
awareness, both when measuring anosognosia as a binary
value with CIRS > 1 or when measuring anosognosia as a
continuous variable. Only when considering a CIRS score > 0
in comparison to any degree of anosognosia, as previously done
by De Carolis et al. (27), was higher percentage of anosognosia
found in EOD compared to LOD. To our knowledge, only
three previous studies had explicitly investigated differences in
anosognosia in EOD and LOD (9–11), reporting conflicting
results. Whereas, previous studies had only focused on AD
or VaD and did not take into account possible different
clinical diagnosis subtypes, in our study, we included different
clinical variants of AD as well as of all the types of dementia
presenting to dementia clinics. This was especially important
considering that non-AD diagnoses are frequent in EOD
patients (12).
Second, we found that in both groups, anosognosia increased
overtime with disease progression and was higher in FTD
patients or, more precisely, in AD and FTD variants associated
with involvement of the frontal lobes. More precisely, we found
that anosognosia was higher in the frontal/dysexecutive variant
of AD and in the behavioral variant of FTD for both early
and current anosognosia, irrespectively of age of dementia
onset. This finding is consistent with neuroimaging studies
showing involvement of frontal cerebral areas in mechanisms
of self-awareness, in both healthy subjects (28) and patients
(29, 30). Recent cognitive models of anosognosia such as the
Cognitive Awareness Model postulated by Agnew and Morris
(2) and revised by Morris and Mograbi (31) hypothesized
that anosognosia derives from the failure in integrating
incoming knowledge with information stored in a personal
database, a system thought to be largely dependent on frontal
brain structures.
Third, we found a strong association with early anosognosia
in the EOD group and neuropsychiatric symptoms, more
precisely with apathy, which has been extensively correlated with
dysfunction of the frontal lobes, especially the medial prefrontal
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cortex (32). Higher levels of early anosognosia were positively
associated with subsequent apathy, suggesting that patients with
lack of awareness at the beginning of their disease are more
at risk to manifest apathy and indifference later in the course
of the disease. This result was independent from time between
first assessment and recruitment and from disease duration.
These novel findings are in line with previous cross-sectional and
longitudinal studies demonstrating that anosognosia and apathy
are strongly associated (33–35) and are both related to frontal
lobe dysfunction (36, 37). Among these, the cross-sectional study
by Spalletta et al. showed that anosognosia was correlated not
only with apathy, but also with the NPI subscores of agitation
and aberrant motor behavior in a large cohort of patients
with AD. Differently from them, we did not find correlations
between anosognosia and other behavioral subdomains beyond
apathy. These differences may be due to the fact that we
included not only AD but also other dementia diagnoses.
Interestingly, the same authors found that anosognosia was
not related to NPI scores in the Mild Cognitive Impairment
phase, suggesting that apathy only occurs in more advanced
phases of diseases. Our longitudinal results add on those of this
previous study showing that early anosognosia correlates with
subsequent apathy. In their longitudinal study, Starkstein and
co-authors hypothesized that the fact that anosognosia predicts
subsequent severe apathy could be explained by an asynchrony
in frontal lobe damage: whereas anosognosia may arise as an
early response to frontal lobe damage, apathy may develop with
further frontal involvement along progression of the disease; as
alternative, they postulated that patients with anosognosia may
fail to search for alternative activities due to their inabilities to
recognize their increasing functional limitations and may lose
motivation and empathy (35). The fact that association between
early anosognosia and apathy was found to be specific for EOD
group was somehow unexpected. We speculate that this may
be related to the fact that EOD may have greater detrimental
effects on global functioning (since it affects people who usually
are still actively engaged in work, family and social activities)
compared to LOD, thus producing higher degree of demotivation
and apathy. Further studies using neuroimaging techniques and
deeper neuropsychological investigations will be useful to better
understand the different relationship between anosognosia and
subsequent apathy in EOD and LOD.
We recognize some limitations for our study. First, we used
only a single method for anosognosia assessment, and it is well
known that different measures may lead to explore different
aspects of awareness (26). Awareness is not an all-or-nothing
phenomenon; it may be that patients are aware of some type
of impairment but not of others. Whereas measurements
based on examiner’s ratings usually refer to global and general
unawareness (including cognitive, behavioral, and functional
abilities), measurements of discrepancy and performance
variably refer to different specific domains depending on
the questionnaire and neuropsychological tests adopted. All
these approaches have significant limitations, and there is no
consensus on themost suitablemethod to determine anosognosia
in dementia; nevertheless, a recent review recommended the
Clinical Insight Rating scale as the most suitable option,
because it is easy and quick to perform in clinical interview
and it also has strong psychometric properties (interrater
correlation 0.91, internal consistency 0.85) (38). Another
limitation is that diagnostic subgroups other than AD and FTD
are relatively small, and this may mask additional awareness
differences among diagnosis subtype and cognitive pattern.
Nevertheless, this is the first study to our knowledge to focus
on EOD-LOD awareness differences in multiple diseases and
we think that investigating anosognosia on the basis of different
neuropathological backgrounds and different clinical variants
may provide deeper knowledge about intrinsic mechanism of
loss of awareness in dementia. Related to this, it should be
noticed that we found that FTD patients showed higher early
anosognosia values in comparison to AD patients, in both EOD
and LOD groups; this result was somehow expected considering
that loss of insight is a prominent clinical manifestation of
FTD. For this reason, when exploring the association between
anosognosia and neuropsychiatric symptoms, we included the
clinical diagnosis as a covariate in the multivariate regression
and found that apathy remained significantly associated with
early anosognosia in the EOD group independently of clinical
diagnosis. Finally, one further limitation of our study is that
apathy was not measured by an appropriated and specific scale
but only with the NPI item; indeed, the main focus of our study
was to investigate the association between anosognosia and
neuropsychiatric symptoms, so we decided to include NPI as a
global scale for our purpose. Future studies with appropriated
scales specific for apathy measure will be useful to better explore
the relationship between anosognosia and apathy.
In conclusion, we showed that anosognosia is frequent in
EOD, either at the beginning or along the progression of
the disease, that it is especially severe in clinical variants
characterized by primary involvement of frontal brain regions,
and that, in EOD, it is associated with the subsequent
development of apathy. These results show that anosognosia
should not be underestimated in EOD but rather considered
a core important clinical feature. It should be recognized by
clinicians and families as early as possible in patients with
or at risk of cognitive decline, to allow better guidance and
management for the patient and caregiver during the progression
of the disease.
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